Genetic influences modulating the radiological severity of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 3, 2010, Pages 476-482

  Marinou, I ^a   Maxwell, J R ^a   Wilson, A G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; AUTOANTIBODY; C REACTIVE PROTEIN; CITRULLINATED PROTEIN ANTIBODY; CYCLOOXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEINASE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; GENE FUNCTION; GENE LOCATION; GENETIC ANALYSIS; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARTHRITIS, RHEUMATOID; CYTOKINES; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE;

EID: 77949495704     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117721     Document Type: Review

References (101)

1. Williams RO, Feldmann M, Maini RN. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis 2000;59(Suppl 1):i75-80.
2. Tanabe N, Maeno M, Suzuki N, et al. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci 2005;77:615-26.
3. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
4. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
5. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
6. Huizinga TW, Landewé RB. Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'? Nat Clin Pract Rheumatol 2005;1:2-3.
7. Möttönen T, Hannonen P, Korpela M, et al.; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
8. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford) 2000;39:939-49.
9. Plant MJ, Williams AL, O'Sullivan MM, et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473- 7.
10. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996;35:1263-8.
11. Smolen JS, Han C, Bala M, et al.; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
12. Verstappen SM, Poole AR, Ionescu M, et al.; Utrecht Rheumatoid Arthritis Cohort Study group (SRU). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006;8:R31.
13. Wollheim FA. Markers of disease in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:200-4.
14. Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:83-8.
15. So A, Chamot AM, Péclat V, et al. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology (Oxford) 1999;38:407-10.
16. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
17. Mewar D, Coote A, Moore DJ, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.
18. Chen JJ, Mu H, Jiang Y, et al. Clinical usefulness of genetic information for predicting radiographic damage in rheumatoid arthritis. J Rheumatol 2002;29:2068-73.
19. van der Helm-van Mil AH, Kern M, Gregersen PK, et al. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis Rheum 2006;54:2028-30.
20. Wagner U, Kaltenhäuser S, Pierer M, et al. Prospective analysis of the impact of HLA-DR and -DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatology (Oxford) 2003;42:553-62.
21. Wagner U, Kaltenhäuser S, Sauer H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51.
22. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52:3813-18.
23. du Montcel ST, Michou L, Petit-Teixeira E, et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005;52:1063- 8.
24. Gourraud PA, Boyer JF, Barnetche T, et al. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for rheumatoid arthritis structural severity. Arthritis Rheum 2006;54:593-9.
25. Mewar D, Marinou I, Coote AL, et al. Association between radiographic severity of rheumatoid arthritis and shared epitope alleles: differing mechanisms of susceptibility and protection. Ann Rheum Dis 2008;67:980-3.
26. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
27. Khanna D, Wu H, Park G, et al.; Western Consortium of Practicing Rheumatologists. Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 2006;54:1105-16.
28. Laurincová B. Interleukin-1 family: from genes to human disease. Acta Univ Palacki Olomuc Fac Med 2000;143:19-29.
29. Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007;104:11742-7.
30. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2004;43(Suppl 3):iii2-9.
31. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford) 2004;43(Suppl 3):iii10-16.
32. Cantagrel A, Navaux F, Loubet-Lescoulié P, et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
33. Buchs N, di Giovine FS, Silvestri T, et al. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001;2:222-8.
34. Pawlik A, Kurzawski M, Florczak M, et al. IL1beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:159-64.
35. Genevay S, Di Giovine FS, Perneger TV, et al. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002;47:303-9.
36. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
37. Marinou I, Healy J, Mewar D, et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007;56:2549-56.
38. Ferrari SL, Ahn-Luong L, Garnero P, et al. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88:255-9.
39. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
40. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006;117:269-74.
41. Pawlik A, Wrzesniewska J, Florczak M, et al. The -590 IL-4 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int 2005;26:48-51.
42. Prots I, Skapenko A, Wendler J, et al. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006;54:1491-500.
43. Marinou I, Till SH, Moore DJ, et al. Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis. Arthritis Res Ther 2008;10:R80.
44. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
45. Katsikis PD, Chu CQ, Brennan FM, et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
46. Huizinga TW, Keijsers V, Yanni G, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000;39:1180-8.
47. Keravala A, Lechman ER, Nash J, et al. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther 2006;8:R91.
48. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
49. Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998;95:9465-70.
50. Kurreeman FA, Schonkeren JJ, Heijmans BT, et al. Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 2004;13:1755-62.
51. Dörr S, Lechtenböhmer N, Rau R, et al. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther 2004;6:R199-207.
52. Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
53. Constantin A, Lauwers-Cancès V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002;46:1754-62.
54. Mattey DL, Nixon NB, Dawes PT, et al. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 2004;5:147-9.
55. Rutter JL, Mitchell TI, Butticè G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5.
56. Tower GB, Coon CC, Benbow U, et al. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta 2002;1586:265-74.
57. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209- 15.
58. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75:330-7.
59. Hill RJ, Zozulya S, Lu YL, et al. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol 2002;30:237-44.
60. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37:1317-19.
61. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004;36:337-8.
62. Veillette A, Latour S, Davidson D. Negative regulation of immunoreceptor signaling. Annu Rev Immunol 2002;20:669-707.
63. Pierer M, Kaltenhäuser S, Arnold S, et al. Association of PTPN22 1858 singlenucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res Ther 2006;8:R75.
64. Steer S, Lad B, Grumley JA, et al. Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect. Arthritis Rheum 2005;52:358-60.
65. Lie BA, Viken MK, Odegård S, et al. Associations between the PTPN22 1858C→T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2007;66:1604-9.
66. Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol Suppl 2004;〈 Volume〉 :1-38.
67. Karlson EW, Chibnik LB, Cui J, et al. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 2008;67:358-63.
68. Lee KH, Kim HS, El-Sohemy A, et al. Cyclooxygenase-2 genotype and rheumatoid arthritis. J Rheumatol 2006;33:1231-4.
69. Rodríguez MR, González-Escribano MF, Aguilar F, et al. Association of NRAMP1 promoter gene polymorphism with the susceptibility and radiological severity of rheumatoid arthritis. Tissue Antigens 2002;59:311-15.
70. Zapico I, Coto E, Rodríguez A, et al. A DNA polymorphism at the alpha2-macroglobulin gene is associated with the severity of rheumatoid arthritis. J Rheumatol 2000;27:2308-11.
71. Thomson W, Barton A, Ke X, et al.; Wellcome Trust Case Control Consortium; YEAR Consortium. Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:1431-3.
72. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
73. Scherer HU, van der Linden MP, Kurreeman FA, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2010;69:567-70.
74. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
75. Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006;439:851-5.
76. Fanciulli M, Norsworthy PJ, Petretto E, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007;39:721-3.
77. Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007;80:1037-54.
78. de Vries N, Prinsen CF, Mensink EB, et al. A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 1993;52:327-31.
79. Jouvenne P, Chaudhary A, Buchs N, et al. Possible genetic association between interleukin-1alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Netw 1999;10:33-6.
80. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, et al. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNFalpha, IL-1beta, and IL-1Ra genes. J Rheumatol 2002;29:212-19.
81. Huang CM, Tsai FJ, Wu JY, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in rheumatoid arthritis. Scand J Rheumatol 2001;30:225-8.
82. Pawlik A, Wrzesniewska J, Florczak M, et al. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005;34:109-13.
83. Oen K, Malleson PN, Cabral DA, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1115- 21.
84. Lard LR, van Gaalen FA, Schonkeren JJ, et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003;48:1841-8.
85. Pawlik A, Kurzawski M, Szklarz BG, et al. Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis. Clin Rheumatol 2005;24:480-4.
86. Mattey DL, Nixon N, Dawes PT, et al. Association of polymorphism in the transforming growth factor β1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 2005;64:1190-4.
87. Kim SY, Han SW, Kim GW, et al. TGF-beta1 polymorphism determines the progression of joint damage in rheumatoid arthritis. Scand J Rheumatol 2004;33:389-94.
88. Mattey DL, Hutchinson D, Dawes PT, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum 2002;46:640-6.
89. Graessler J, Verlohren M, Graessler A, et al. Association of chondromodulin-II Val58Ile polymorphism with radiographic joint destruction in rheumatoid arthritis. J Rheumatol 2005;32:1654-61.
90. Zapico I, Coto E, Rodríguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000;1:288-9.
91. Pokorny V, McQueen F, Yeoman S, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005;64:487-90.
92. Joven B, González N, Aguilar F, et al. Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis Rheum 2005;52:354- 6.
93. Graudal NA, Madsen HO, Tarp U, et al. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000;43:515-21.
94. Ip WK, Lau YL, Chan SY, et al. Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum 2000;43:1679-87.
95. Gupta B, Agrawal C, Raghav SK, et al. Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples. J Hum Genet 2005;50:583- 91.
96. Jacobsen S, Madsen HO, Klarlund M, et al.; TIRA Group. The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. TIRA Group. J Rheumatol 2001;28:935-42.
97. Barton A, Platt H, Salway F, et al. Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. J Rheumatol 2004;31:442-7.
98. Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1093-7.
99. Macchioni P, Nicoli D, Casali B, et al. The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. Clin Exp Rheumatol 2007;25:416-21.
100. Kurreeman FA, Padyukov L, Marques RB, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007;4:e278.
101. Wagener FA, Toonen EJ, Wigman L, et al. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis Rheum 2008;58:3388-93.